The Independent Uganda: You get the Truth we Pay the Price
QCIL H1 profit climbs 6.2% to Shs 23.9bn
Kampala, Uganda | JULIUS BUSINGE | Quality Chemical Industries Ltd (Qcil), Uganda’s pharmaceutical manufacturer, is celebrating higher profits in the first half of its financial year, a positive sign for Ugandans who rely on locally produced, affordable medicines.
The company posted a 6.2% rise in profit after tax, hitting Shs23.9 billion for the six months ending September 30, 2025, up from Shs22.1 billion last year. However, it wasn’t all smooth sailing. Revenue dipped slightly by 2.6%, affected by reduced export earnings and a stronger Ugandan shilling.
“Our focus on efficiency, innovation, and careful cost management is helping us provide more affordable healthcare solutions,” said Qcil Board Chairman Emmanuel Katongole. Indeed, the results show that Qcil’s strategy is paying off.
Qcil’s gross profit margin improved to 42.4% from 38.6% last year, thanks to more efficient production and a focus on locally produced, affordable medicines. Cash from operations also surged to Shs51.4 billion from Shs9.3 billion, which gives the company more room to invest in new production lines and keep medicines flowing to patients.
To expand more access to medicine, Qcil introduced 16 new medicines covering malaria, diabetes, blood pressure, infections, allergies, and fungal diseases, which means more patients get the medicines they need, right here at home.
The Qcil Chief Executive Officer, Ajay Kumar Pal, added that the company’s growth will continue to benefit the public.
“The first half of FY26 demonstrates our operational discipline and continued focus on efficiency,” said Mr Ajay. “We are focusing on growth while building a stronger foundation for long-term expansion across introduced injectable and tuberculosis product lines, further cementing Qcil’s position as a regional hub for quality pharmaceutical manufacturing.”
The company is also building a second factory at its Luzira complex, including a modern injectable medicines line with a goal to produce more life-saving drugs, create more jobs, and promote import substitution.
Also, the Board proposed an interim dividend of Shs4.2 per share, up from Shs3.5, rewarding shareholders while still funding growth that benefits the public.
Looking ahead, Qcil plans to expand medicine distribution across Uganda and Africa, invest in technology for better production quality, and increase its product range.
